These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 35681598)

  • 1. Inhibition of a Mitochondrial Potassium Channel in Combination with Gemcitabine and Abraxane Drastically Reduces Pancreatic Ductal Adenocarcinoma in an Immunocompetent Orthotopic Murine Model.
    Li W; Wilson GC; Bachmann M; Wang J; Mattarei A; Paradisi C; Edwards MJ; Szabo I; Gulbins E; Ahmad SA; Patel SH
    Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sphingosine is involved in PAPTP-induced death of pancreas cancer cells by interfering with mitochondrial functions.
    Patel SH; Wilson GC; Wu Y; Keitsch S; Wilker B; Mattarei A; Ahmad SA; Szabo I; Gulbins E
    J Mol Med (Berl); 2024 Jul; 102(7):947-959. PubMed ID: 38780771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous targeting of mitochondrial Kv1.3 and lysosomal acid sphingomyelinase amplifies killing of pancreatic ductal adenocarcinoma cells in vitro and in vivo.
    Patel SH; Bachmann M; Kadow S; Wilson GC; Abdel-Salam MML; Xu K; Keitsch S; Soddemann M; Wilker B; Becker KA; Carpinteiro A; Ahmad SA; Szabo I; Gulbins E
    J Mol Med (Berl); 2023 Mar; 101(3):295-310. PubMed ID: 36790532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the Potassium Channel Kv1.3 Kills Glioblastoma Cells.
    Venturini E; Leanza L; Azzolini M; Kadow S; Mattarei A; Weller M; Tabatabai G; Edwards MJ; Zoratti M; Paradisi C; Szabò I; Gulbins E; Becker KA
    Neurosignals; 2017; 25(1):26-38. PubMed ID: 28869943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological modulation of Kv1.3 potassium channel selectively triggers pathological B lymphocyte apoptosis in vivo in a genetic CLL model.
    Severin F; Urbani A; Varanita T; Bachmann M; Azzolini M; Martini V; Pizzi M; Tos APD; Frezzato F; Mattarei A; Ghia P; Bertilaccio MTS; Gulbins E; Paradisi C; Zoratti M; Semenzato GC; Leanza L; Trentin L; Szabò I
    J Exp Clin Cancer Res; 2022 Feb; 41(1):64. PubMed ID: 35172855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitochondrial Kv1.3 Channels as Target for Treatment of Multiple Myeloma.
    Kadow S; Schumacher F; Kramer M; Hessler G; Scholtysik R; Oubari S; Johansson P; Hüttmann A; Reinhardt HC; Kleuser B; Zoratti M; Mattarei A; Szabò I; Gulbins E; Carpinteiro A
    Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of PI-3-K and AKT Amplifies Kv1.3 Inhibitor-Induced Death of Human T Leukemia Cells.
    Bergermann T; Born L; Ferguson F; Latkovic P; Scheul A; Sonnenschein N; Leanza L; Keitsch S; Sehl C; Wilker B; Edwards MJ; Zoratti M; Paradisi C; Kohnen M; Szabo I; Becker KA; Carpinteiro A
    Cell Physiol Biochem; 2019; 53(S1):1-10. PubMed ID: 31804046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of Proliferation by a Mitochondrial Potassium Channel in Pancreatic Ductal Adenocarcinoma Cells.
    Peruzzo R; Mattarei A; Romio M; Paradisi C; Zoratti M; Szabò I; Leanza L
    Front Oncol; 2017; 7():239. PubMed ID: 29034212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic effect of Abraxane that combines human IL15 fused with an albumin-binding domain on murine models of pancreatic ductal adenocarcinoma.
    Hsu FT; Tsai CL; Chiang IT; Lan KH; Yueh PF; Liang WY; Lin CS; Chao Y; Lan KL
    J Cell Mol Med; 2022 Apr; 26(7):1955-1968. PubMed ID: 35174623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Voltage-Gated Potassium Channel Kv1.3 as a Target in Therapy of Cancer.
    Teisseyre A; Palko-Labuz A; Sroda-Pomianek K; Michalak K
    Front Oncol; 2019; 9():933. PubMed ID: 31612103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-reducing effect of the clinically used drug clofazimine in a SCID mouse model of pancreatic ductal adenocarcinoma.
    Zaccagnino A; Managò A; Leanza L; Gontarewitz A; Linder B; Azzolini M; Biasutto L; Zoratti M; Peruzzo R; Legler K; Trauzold A; Kalthoff H; Szabo I
    Oncotarget; 2017 Jun; 8(24):38276-38293. PubMed ID: 27542263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inoculation of Pan02 cells produces tumor nodules in mouse pancreas: Characterization of a novel orthotopic pancreatic ductal adenocarcinoma tumor model for interventional studies.
    Griffin JI; Chen X; Duan L; Mu Q; Ho RJY
    PLoS One; 2024; 19(3):e0300723. PubMed ID: 38547077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct Pharmacological Targeting of a Mitochondrial Ion Channel Selectively Kills Tumor Cells In Vivo.
    Leanza L; Romio M; Becker KA; Azzolini M; Trentin L; Managò A; Venturini E; Zaccagnino A; Mattarei A; Carraretto L; Urbani A; Kadow S; Biasutto L; Martini V; Severin F; Peruzzo R; Trimarco V; Egberts JH; Hauser C; Visentin A; Semenzato G; Kalthoff H; Zoratti M; Gulbins E; Paradisi C; Szabo I
    Cancer Cell; 2017 Apr; 31(4):516-531.e10. PubMed ID: 28399409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of invasive pancreatic cancer: restoring cell apoptosis by activating mitochondrial p53.
    Cheng J; Okolotowicz KJ; Ryan D; Mose E; Lowy AM; Cashman JR
    Am J Cancer Res; 2019; 9(2):390-405. PubMed ID: 30906636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic modulation enhances immunotherapy for pancreatic ductal adenocarcinoma.
    Li Y; Hong YK; Wang X; Pandit H; Zheng Q; Yu Y; Shi X; Chen Y; Tan M; Pulliam Z; Bhutiani N; Lin A; Badach J; Zhang P; Martin RC
    Clin Transl Immunology; 2022; 11(12):e1430. PubMed ID: 36452477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Involvement of angiotensin II type 2 receptor (AT2R) signaling in human pancreatic ductal adenocarcinoma (PDAC): a novel AT2R agonist effectively attenuates growth of PDAC grafts in mice.
    Ishiguro S; Yoshimura K; Tsunedomi R; Oka M; Takao S; Inui M; Kawabata A; Wall T; Magafa V; Cordopatis P; Tzakos AG; Tamura M
    Cancer Biol Ther; 2015; 16(2):307-16. PubMed ID: 25756513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitochondrial Kv1.3: a New Target in Cancer Biology?
    Checchetto V; Prosdocimi E; Leanza L
    Cell Physiol Biochem; 2019; 53(S1):52-62. PubMed ID: 31854954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deregulation of 2 potassium channels in pancreas adenocarcinomas: implication of KV1.3 gene promoter methylation.
    Brevet M; Fucks D; Chatelain D; Regimbeau JM; Delcenserie R; Sevestre H; Ouadid-Ahidouch H
    Pancreas; 2009 Aug; 38(6):649-54. PubMed ID: 19465885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma.
    Xie Y; Zhu S; Zhong M; Yang M; Sun X; Liu J; Kroemer G; Lotze M; Zeh HJ; Kang R; Tang D
    Gastroenterology; 2017 Nov; 153(5):1429-1443.e5. PubMed ID: 28764929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Orexin-A/OX1R System Induces Cell Death in Pancreatic Cancer Cells Resistant to Gemcitabine and Nab-Paclitaxel Treatment.
    Voisin T; Nicole P; Gratio V; Chassac A; Mansour D; Rebours V; Couvelard A; Couvineau A
    Front Oncol; 2022; 12():904327. PubMed ID: 35747788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.